Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-09-17
1998-08-18
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546153, 546174, 546175, 546176, 546180, C07D21330, C07D21514, C07D40110, A61K 3147
Patent
active
057959005
ABSTRACT:
Compounds having the formula: ##STR1## wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R.sup.1 and R.sup.2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R.sup.3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH.dbd.N--O--A--COM, (c) CH.sub.2 --O--N.dbd.A--COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) --OR.sup.6, (c) --NR.sup.7 R.sup.8, (d)--NR.sup.6 SO.sub.2 R.sup.9, (e)-NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.
REFERENCES:
patent: 4970215 (1990-11-01), Mohrs et al.
patent: 5326883 (1994-07-01), Brooks
patent: 5358955 (1994-10-01), Brooks et al.
patent: 5512581 (1996-04-01), Brooks et al.
P. Prasit; A New Class of Leukotriene Biosynthesis Inhibitors: The Development of ((40(4-Chlorophenyl)-1(4-(-Quinolinylmethoxy)Phenyl)Butyl)Thio)Acetic Acid, L-674,636 Biorganic & Medicinal Chemistry Letters, vol. 1, No. 11, pp. 645-648, 1991.
Musser et al; 5-Lipoxygenase: Properties, Pharmacolgy, and The Quinolinyl (Bridged) Aryl Class of Inhibitors; Journ of Med Chem 1992, vol. 35, No. 14 pp. 2501-2524.
A.J. Mancuso,et al. Oxidation of Long-Chain and Related Alcohols to Carbonyls by Dimethyl Sulfoxide "Activated" by Oxalyl Chloride J. Org. Chem,. vol. 43,No. 12, 1978, pp. 2480-2482.
O. Mitsunobu, Sunthesis International Journal of Methods in Synthetic Organic Chemistry 1981 No. 1: Jan., pp. 1-28.
S. Berge, et al. Pharmaceutical Salts, Journal of Pharm Sciences Jan 1977 vol 66 No. 1, pp. 1-19.
T. Rao et al. Evaluation of 5-Liboxygenase Inhibitors, Zileuton, A-78773 and ICI-D-2138 in an Ionophore (A-23187) Induced Pleural Inflamation Model in the Rat, Life Sciences, vol. 53, pp. PL 147-152, 1993.
Bhatia Pramila
Brooks Clint D.
Craig Richard A.
Gunn David E.
Kolasa Teodozyj
Abbott Laboratories
Ivy C. Warren
M. Mach D. Margaret
Yang Frank Z.
LandOfFree
Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as i does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as i, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as i will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1115056